文献速递主动脉疾病外周动脉疾病

三种器械平台用于主动脉分叉覆膜支架重建的结局分析

Outcomes Analysis of 3 Different Device Platforms for the Covered Endovascular Reconstruction of the Aortic Bifurcation.
PubMed 文献 · J Endovasc Ther · 2026-09-15

本研究为多中心回顾性队列研究,比较三种腔内平台行主动脉分叉覆膜支架重建(CERAB)的结局。共分析220例CERAB,VBX组132例、AFX/AFX-2组60例、BeGraft组28例。技术成功率98.6%,中位随访21个月,三组总生存率和免于CERAB相关再干预率无显著差异。

要点

  • CERAB技术在各平台均安全可行,中远期耐久性可接受。
  • 三组总生存率和免于CERAB相关再干预率无显著差异。
  • VBX组患者年龄更大,AFX/AFX-2组严重肢体缺血比例最低。

核心结论

  • 在主动脉髂动脉闭塞性疾病患者中,CERAB技术安全且中远期耐久性可接受,不依赖于腔内平台类型。

研究设计与样本

  • 研究者发起的、无资助的多中心观察性回顾性队列研究,纳入2016年3月1日至2024年9月30日期间所有CERAB病例。
  • 共分析220例(96.9%)CERAB,其中VBX组132例(60.0%)、AFX/AFX-2组60例(27.3%)、BeGraft组28例(12.7%)。

主要发现

  • 技术成功217例(98.6%),3例失败均发生在VBX组。
  • 中位随访21个月(IQR 9-30),三组间有差异(BeGraft 21个月 vs VBX 13.5个月 vs AFX/AFX-2 25个月,P=.001)。
  • 估计生存率12个月92%±0.2(95%CI 87.0-94.9)、24个月87%±0.3(95%CI 81.4-91.6)、60个月76%±0.5(95%CI 64.6-84.2)。
  • 免于CERAB相关再干预率12个月94%±0.2(95%CI 89.7-96.5)、24个月93%±0.2(95%CI 88.3-95.9)、60个月89%±0.3(95%CI 81.4-94.1)。
  • 三组间生存率和免于CERAB相关再干预率无显著差异(P=.696和P=.497)。

临床怎么用

  • CERAB可用于主动脉髂动脉闭塞性疾病,三种腔内平台均可选择,中期耐久性不依赖于器械类型。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To analyze the major aortoiliac obstructive disease (AIOD)-related outcomes after covered endovascular reconstruction of aortic bifurcation (CERAB), comparing 3 different endovascular platforms. MATERIALS AND METHODS: It is a physician-initiated, unsupported, multicenter, observational, retrospective, cohort study. We identified all CERABs between March 1, 2016 and September 30, 2024. We compared 3 different endovascular platforms: Viabahn VBX (W.L. Gore, Flagstaff; Arizona), AFX/AFX-2 (Endologix, Irvine, California), and BeGraft (Hechingen, Germany). Inclusion criteria were CERAB procedure for primary or de novo AIOD; exclusion criteria were CERAB using a combination of different platforms, traumatic lesions, and missing preoperative/follow-up data. Specifically, for the purposes of this study, the primary outcomes were overall survival and CERAB-related reintervention. RESULTS: We analyzed 220 (96.9%) CERABs: 132 (60.0%) with the VBX, 60 (27.3%) with the AFX/AFX-2, and 28 (12.7%) with the BeGraft. Patients in the VBX group were older [median-25th-75th interquartile: VBX, 71 [IQR, 65.2-77] vs AFX/AFX-2, 64 [IQR, 59-72] vs BeGraft 68 [IQR, 55.7-73.5], P = .002], whereas AFX/AFX-2 group had the lowest rate of critical limb-threatening ischemia as presenting scenario (VBX, 36.4% vs AFX/AFX-2, 18.2% vs BeGraft 35.7%, while AFX/AFX-2 P = .039). Technical success was achieved in 217 (98.6%) procedures: all 3 failures occurred in the VBX group. The median follow-up was 21 months (IQR, 9-30), with a difference among the groups (months: BeGraft 21 [IQR, 10.7-42] vs VBX, 13.5 [IQR, 6-26] vs AFX/AFX-2, 25 [IQR, 17.2-38.7], P = .001]. Estimated survival was 92% ± 0.2 (95% CI, 87.0-94.9) at 12 months, 87% ± 0.3 (95% CI, 81.4-91.6) at 24 months, and 76 ± 0.5 (95% CI, 64.6-84.2) at 60 months. The freedom from CERAB-related reintervention rate was 94% ± 0.2 (95% CI, 89.7-96.5) at 12 months, 93% ± 0.2 (95% CI, 88.3-95.9) at 24 months, and 89 ± 0.3 (95% CI, 81.4-94.1) at 60 months. Survival and freedom from CERAB-related reintervention did not differ among the groups (P = .696 and P = .497, respectively). CONCLUSION: In patients with AIOD, the CERAB technique proved to be safe procedure with acceptable durability at mid- to long-term follow-up independently of the type of endovascular platform.Clinical ImpactWith the current technical expertise and wide availability of a variety of endovascular platforms and geometries of reconstruction, the Covered Endovascular Reconstruction of the Aortic Bifurcation (CERAB) endovascular reconstruction of aorto-iliac obstructive disease proved to be a satisfactory technique based on durable results at mid-term follow-up with independently of the device used.

来源:J Endovasc Ther,查看原文。版权归原作者所有。

引用

  1. Piffaretti G, Zacà S, Palughi M, et al. Outcomes Analysis of 3 Different Device Platforms for the Covered Endovascular Reconstruction of the Aortic Bifurcation. J Endovasc Ther. 2026. PMID: 42740645. doi:10.1177/15266028261484791

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。